Heart Failure tachycardia, cardiomyopathy
Conditions
Interventions
We will randomize the patients with heart failure with reduced left ventricular ejection fraction into the ibabradine arm and the control arm and follow them for six months.
D046650
bradycardia, tachycardia
Sponsors
Kinugawa Koichiro
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Heart failure with reduced left ventricular ejection fraction due to ischemic or non-ischemic cardiomyopathy 2. Refractory to the up-titration of beta-blocker due to failing symptom 3. Sinus rhythm, heart rhythm above 75 bpm, and systolic blood pressure above 90 mmHg 4. New York Heart Association functional class III or IV
Exclusion criteria
Exclusion criteria: 1. Those with a plan of surgical interventions during the observational period 2. Allergy to the beta-blocker 3. Heart rate below 75 bpm or systolic blood pressure below 90 mmHg 4. Chronic obstructive pulmonary disease or bronchial asthma is not a contraindication
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| A daily dose of beta-blocker equivalent to the carvedilol at six months | — |
Secondary
| Measure | Time frame |
|---|---|
| Six-month left ventricular end-diastolic diameter and ejection fraction Six-month plasma B-type natriuretic peptide level Six-month six-minute walk distance Six-month readmission due to heart failure | — |
Contacts
Public ContactKoichiro Kinugawa
Toyama University Hospital
Outcome results
None listed